Abstract
High-resolution imaging methods (HRIMs) and biomarkers present the second step of pancreatic cancer (PC) diagnostics in at-risk individuals. These include patients with positive risk factors, early symptoms, nonresponders to the initial antidiabetic therapy, patients older than 50 years of age with new-onset unstable diabetes requiring insulin as well as patients with long-term insulin-non-dependent diabetes and recent (up to 6 months) failure of antidiabetic therapy. The procedures should be started without delay and the co-operation between the primary and tertiary medical centers is highly desirable. An early indication of HRIMs and biomarkers is a prerequisite for the diagnosis of a resectable PC. This publication reviews the recent contribution of HRIMs and biomarkers toward an early diagnosis of PC.
MeSH terms
-
Adenoma / diagnostic imaging*
-
Adenoma / genetics
-
Adenoma / metabolism
-
Antibodies / metabolism
-
Biomarkers
-
Carcinoma in Situ / diagnostic imaging*
-
Carcinoma in Situ / genetics
-
Carcinoma in Situ / metabolism
-
Carcinoma, Pancreatic Ductal / diagnostic imaging*
-
Carcinoma, Pancreatic Ductal / genetics
-
Carcinoma, Pancreatic Ductal / metabolism
-
Cholangiopancreatography, Endoscopic Retrograde
-
Cholangiopancreatography, Magnetic Resonance
-
Early Detection of Cancer / methods*
-
Elasticity Imaging Techniques
-
Endosonography
-
Humans
-
Magnetic Resonance Imaging
-
MicroRNAs / genetics*
-
Multidetector Computed Tomography
-
Neoplasms, Cystic, Mucinous, and Serous / diagnostic imaging*
-
Neoplasms, Cystic, Mucinous, and Serous / genetics
-
Neoplasms, Cystic, Mucinous, and Serous / metabolism
-
Pancreatic Neoplasms / diagnostic imaging*
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / metabolism
-
Plectin / metabolism
-
Positron Emission Tomography Computed Tomography
-
Ultrasonography
Substances
-
Antibodies
-
Biomarkers
-
DAS-1 protein, human
-
MicroRNAs
-
PLEC protein, human
-
Plectin